Latest news with #Intuitive
Yahoo
19 hours ago
- Business
- Yahoo
Intuitive Surgical's Da Vinci 5 System Receives CE Mark, Expands Advanced Robotic Surgery Access Across Europe
Intuitive Surgical Inc. (NASDAQ:ISRG) is one of the best US stocks to buy and hold in 2025. On July 2, Intuitive Surgical announced that its latest da Vinci 5 Surgical System received CE mark approval. This regulatory milestone enables the system's use across adult and pediatric patients in Europe for a spectrum of minimally invasive endoscopic procedures, such as abdominopelvic and thoracoscopic surgeries in urology, gynecology, and general laparoscopy. The da Vinci 5 introduces 50+ enhancements on the foundational da Vinci Xi Surgical System. Key innovations include first-of-its-kind Force Feedback-enabled technology, which allows surgeons to sense pressure and tension during operations. It also features Intuitive's most realistic 3D vision system to date. The system supports 10,000x more computing power than previous models. There's also greater surgeon autonomy through integrated components controlled at the fingertips, a universal user interface for care teams, and dynamic assistance to automate select tasks. A medical team performing minimally invasive surgery with a da Vinci Surgical System. In 2024, the US FDA had already granted 510(k) clearance for the da Vinci 5 Surgical System for use in urology, general, gynecology, and thoracic procedures in adults. In 2024, surgeons performed 410,000+ procedures in Europe using da Vinci systems, contributing to ~17 million procedures performed worldwide to date with Intuitive's technology. Intuitive Surgical Inc. (NASDAQ:ISRG) develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care. While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 days ago
- Business
- Yahoo
Intuitive receives CE mark approval for robotic-assisted surgical system
Intuitive's multi-port robotic-assisted surgical system, da Vinci 5, has secured the CE mark approval for use in both adult and paediatric patients in Europe. This approval allows the system to be utilised for a wide range of minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic procedures, including those in gynaecology, urology, and general laparoscopy. The system builds on the functional design of the da Vinci Xi Surgical System. It features over 150 improvements, contributing to the da Vinci surgical system portfolio that has been leveraged in more than 410,000 procedures in Europe last year. The system delivers improved surgical senses, including Force Feedback-enabled technology and an ergonomic surgeon console for supporting surgeon career longevity. It also streamlines workflow with a universal user interface for care teams and integrates assistance to automate chosen tasks. Additionally, the surgical system delivers actionable insights via an intelligent platform that claims to have 10,000 times more computing power, with new sensors, processors, and software. This provides surgeons with usable data aiding them to quantify, understand, and enhance their surgical performance. Intuitive CEO Dave Rosa said: 'At Intuitive, we're focused on providing healthcare systems across Europe and around the world with thoughtful innovation that solves problems today and into the future. 'After over a decade of careful development, da Vinci 5 is the most advanced and integrated platform we've ever created – designed to enable better outcomes, efficiency, and insights for the future of minimally invasive care.' Last year, da Vinci 5 was cleared by the US Food and Drug Administration for use in various surgical procedures for adults, spanning general, gynaecology, urology, and thoracic. "Intuitive receives CE mark approval for robotic-assisted surgical system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
12-06-2025
- Health
- Yahoo
Great Falls Hospital introduces new technology available in diagnosing lung cancer
Great Falls Hospital unveiled a new diagnostic tool on Tuesday that is now available to patients in northcentral Montana for the first time. The Ion, a robotic device from the medical company Intuitive that offers a new alternative in diagnosing lung cancers, is now in use at the hospital's pulmonary department. Great Falls Hospital is the first medical center in the area to use the Ion robot and third in Montana along with facilities in Billings and Kalispell. Intuitive bills the Ion as a device that offers a minimally invasive procedure that can also help provide earlier detection of lung cancers. If a patient has nodules in the lungs that show up on a CT scan, the Ion can take the scan and creates a 'Google Maps' of sorts of the lungs and can show the pulmonologist the direct path to the growth. The Ion uses a 2-millimeter catheter that is inserted into the lungs via the patient's throat, said Dr. Megan Sisk, one of two pulmonologists at Great Falls Hospital trained on the robot, along with Dr. John Mazur. The technology has been on the market since 2019, according to Intuitive's Katie Bosler. A camera is then inserted into the tube that is attached to the Ion's robotic arm. The pulmonologist controls the camera's path through the line with two wheel-like controls, with one guiding the path forward and the other vertical and horizontal movement. A blue line guides the doctor through the lung's airways directly to the nodule, at which point the camera is removed and replaced with a biopsy tool to collect a sample. 'Before (using the Ion), you couldn't get to a nodule this far out,' Sisk said. 'The previous technology, you could only get a third or half of the way there because you didn't have anything to reach further. The airways are small, and this catheter is so soft and flexible, we're able to navigate out further and deeper than we've ever been able to.' Prior to this form of bronchoscopy, the diagnostic method for lung growths was a 'CT-guided needle biopsy,' which involved inserting a large needle through the ribs into the outer layer of the lung, said Sam Baker of Intuitive. Patients had a 25% chance of having a popped lung or some other complication with a needle biopsy that would require hospitalization, according to Baker, while the risk of further complications with the Ion procedure is 2 to 4%. The patient undergoes anesthesia for the procedure, which takes around 30 to 60 minutes to complete, Sisk said. The hospital has already seen a handful of patients for the Ion bronchoscopy over the past month since it has been in operation. Great Falls Hospital CEO Mark Robinson said the technology has already paid dividends in early detection of lung cancer in patients. 'After (Sisk's) first few cases, she sent me a text and she goes, 'We've got two stage ones, both of which otherwise, I wouldn't have been able to get to without this technology,'' Robinson said. 'We said to ourselves, 'What an investment in people here, what an investment in being able to stage cancers earlier and give people years of their life back because we can treat and/or cure through identifying, diagnosing, and then finding the curative path.'' Sisk said in earlier methods of lung biopsies, it could take as long as 12 weeks to reach a diagnosis and as many as 20 weeks between procedure and the start of treatment. She said that with the Ion technology, she is able to get referrals in about a week after the initial consultation for the procedure. Survival rates decrease by 13% every six weeks in lung cancer patients, and the five-year survival rate for the most common lung cancer is 28%, according to statistics from Great Falls Hospital. Evidence of kidney, breast and skin cancers can also be found in the lungs, Sisk said. Robinson said the hospital is proud to offer the procedure to Great Falls and the surrounding communities, significantly cutting down the travel for potential patients who would have otherwise had to drive hundreds of miles to have it available. 'You think about in Montana, think about the seasons,' Robinson said. 'How hard is it is to get to certain places when you're in Great Falls…It's hard to get to Kalispell in the winter. It's hard to get to Billings in poor conditions. We're super happy with hopefully giving patients the access they need and deserve, right here in Great Falls, with this high level of acuity that they otherwise wouldn't get in a small community that they're coming from.' This article originally appeared on Great Falls Tribune: Great Falls Hospital offers new technology for early cancer detection
Yahoo
10-06-2025
- Business
- Yahoo
Intuitive Surgical analyst raises eyebrows with new stock price target
Intuitive Surgical analyst raises eyebrows with new stock price target originally appeared on TheStreet. Jim Cramer wants answers. The CNBC anchor and Mad Money maven wants to know why Deutsche Bank was being so rough on Intuitive Surgical () . The investment firm downgraded the biotech to sell from hold and slashed its stock price target to $440 from $515. 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰 "This is quite a controversial call," Cramer said on CNBC's Squawk on The Street, "because this is a premier fast-growing company, premier super growth, and I want to find out more about it." The Sunnyvale, Calif., company, founded in 1995, specializes in robotic-assisted surgery equipment, most notably the Da Vinci surgical systems, which use a minimally invasive approach. Intuitive Surgical's shares were down 6.1% at last check but are up 25.4% from a year ago. Deutsche Bank said in a note to investors on June 9 that remanufactured instruments are going to increasingly encroach on Intuitive's instruments and accessories segment over the next few years. The investment firm expects a growing number of Intuitive's customers to explore adopting remanufactured instruments, given potentially significant profitability gains. The firm cited its discussions with multiple robotic surgery programs. Remanufactured instruments are previously used surgical instruments that have been rigorously overhauled. More Tech Stocks: Palantir gets great news from the Pentagon Analyst has blunt words on Trump's iPhone tariff plans OpenAI teams up with legendary Apple exec Deutsche Bank says 46% of Intuitive's U.S. instruments and accessories revenue could be at risk of encroachment by third-party-remanufactured devices. The firm's model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Cramer begged to differ. "This is a pristine company and people who know this company have been rewarded repeatedly by owning it," he said. Just a few days earlier, on June 5, Erste Group analyst Hans Engel upgraded Intuitive Surgical to buy from hold, according to The Fly. The company's operating margin should widen again in 2026 and profit growth should increase significantly, the analyst said. Engel said that he expected the share price to rise further due to Intuitive's expected acceleration in growth. On April 2 Intuitive Surgical beat Wall Street's first-quarter earnings and revenue expectations, with sales increasing 19% from a year ago to $2.25 billion. "Our business performed well in the first quarter of the year with physicians using our products at the high end of our expectations, driven by strong procedure growth in core general surgery in the United States, and strong procedures outside the United States," CEO Gary Guthart told analysts. "New system placements in the quarter were solid with particular strength in the U.S." First-quarter 2025 instruments and accessories revenue increased 18% from a year earlier to $1.37 billion, driven primarily by roughly 17% growth in da Vinci procedure volume and about 58% volume growth in the Ion procedure, which gives doctors a nonsurgical way to biopsy lung nodules."Mad Money" marked its 20th anniversary this year and Cramer, who co-founded TheStreet in 1996, said Intuitive Surgical was the eighth best performer of the 'Mad Money era.' "This is another name that we found early on," he said. "I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change." He added that the company was now a '$184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started." "I think this is as relevant as ever," Cramer said. "I'm proud to be a huge supporter of this.' The company recently said that effective July 1, Guthart would become executive chairman while Dave Rosa, currently president, would become CEO. On May 22, Citi raised its price target on Intuitive Surgical to $650 from $590 and kept a buy rating on the shares. The firm updated models in medical technology following the Q1 reports. Underlying fundamentals in the sector appear intact, including volumes, pricing, and capital spending, the investment firm said. In March, The Robot Report said that while Intuitive Surgical. remains the leading surgical robotics provider 'other companies with savvy strategies are generating buzz and raising money.' The report listed several companies, including Medtronic () , Stryker () and CMR Surgical, which reportedly has brought in advisers to explore a potential Surgical analyst raises eyebrows with new stock price target first appeared on TheStreet on Jun 9, 2025 This story was originally reported by TheStreet on Jun 9, 2025, where it first appeared.
Miami Herald
09-06-2025
- Business
- Miami Herald
Intuitive Surgical analyst raises eyebrows with new stock price target
Jim Cramer wants answers. The CNBC anchor and Mad Money maven wants to know why Deutsche Bank was being so rough on Intuitive Surgical (ISRG) . The investment firm downgraded the biotech to sell from hold and slashed its stock price target to $440 from $515. Don't miss the move: Subscribe to TheStreet's free daily newsletter "This is quite a controversial call," Cramer said on CNBC's Squawk on The Street, "because this is a premier fast-growing company, premier super growth, and I want to find out more about it." The Sunnyvale, Calif., company, founded in 1995, specializes in robotic-assisted surgery equipment, most notably the Da Vinci surgical systems, which use a minimally invasive approach. Intuitive Surgical's shares were down 6.1% at last check but are up 25.4% from a year ago. Deutsche Bank said in a note to investors on June 9 that remanufactured instruments are going to increasingly encroach on Intuitive's instruments and accessories segment over the next few years. The investment firm expects a growing number of Intuitive's customers to explore adopting remanufactured instruments, given potentially significant profitability gains. The firm cited its discussions with multiple robotic surgery programs. Remanufactured instruments are previously used surgical instruments that have been rigorously overhauled. More Tech Stocks: Palantir gets great news from the PentagonAnalyst has blunt words on Trump's iPhone tariff plansOpenAI teams up with legendary Apple exec Deutsche Bank says 46% of Intuitive's U.S. instruments and accessories revenue could be at risk of encroachment by third-party-remanufactured devices. The firm's model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Cramer begged to differ. "This is a pristine company and people who know this company have been rewarded repeatedly by owning it," he said. Just a few days earlier, on June 5, Erste Group analyst Hans Engel upgraded Intuitive Surgical to buy from hold, according to The Fly. The company's operating margin should widen again in 2026 and profit growth should increase significantly, the analyst said. Engel said that he expected the share price to rise further due to Intuitive's expected acceleration in growth. On April 2 Intuitive Surgical beat Wall Street's first-quarter earnings and revenue expectations, with sales increasing 19% from a year ago to $2.25 billion. "Our business performed well in the first quarter of the year with physicians using our products at the high end of our expectations, driven by strong procedure growth in core general surgery in the United States, and strong procedures outside the United States," CEO Gary Guthart told analysts. "New system placements in the quarter were solid with particular strength in the U.S." First-quarter 2025 instruments and accessories revenue increased 18% from a year earlier to $1.37 billion, driven primarily by roughly 17% growth in da Vinci procedure volume and about 58% volume growth in the Ion procedure, which gives doctors a nonsurgical way to biopsy lung nodules. Related: Analysts reboot Intuitive Surgical stock price target ahead of earnings "Mad Money" marked its 20th anniversary this year and Cramer, who co-founded TheStreet in 1996, said Intuitive Surgical was the eighth best performer of the "Mad Money era." "This is another name that we found early on," he said. "I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change." He added that the company was now a "$184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started." "I think this is as relevant as ever," Cramer said. "I'm proud to be a huge supporter of this." The company recently said that effective July 1, Guthart would become executive chairman while Dave Rosa, currently president, would become CEO. On May 22, Citi raised its price target on Intuitive Surgical to $650 from $590 and kept a buy rating on the shares. The firm updated models in medical technology following the Q1 reports. Underlying fundamentals in the sector appear intact, including volumes, pricing, and capital spending, the investment firm said. In March, The Robot Report said that while Intuitive Surgical. remains the leading surgical robotics provider "other companies with savvy strategies are generating buzz and raising money." The report listed several companies, including Medtronic (MDT) , Stryker (SYK) and CMR Surgical, which reportedly has brought in advisers to explore a potential sale. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
